english.prescrire.org > Prescrire International > N°233 - January 2022

n°233

January 2022

Issue Contents
Editorial

Free  A critical eye

p.3

Marketing Authorisations


Crizanlizumab (Adakveo°) to prevent vaso-­occlusive crises in sickle-cell disease

p.5-8
No proven clinical advantages, either as an adjunct to or instead of hydroxycarbamide

Fenfluramine (Fintepla°) in Dravet syndrome

p.9-11
Higher incidence of convulsive status epilepticus, and ­serious cardio­vascular risks in the long term

Anakinra (Kineret°) and familial Mediterranean fever

p.12

Avelumab (Bavencio°) as maintenance treatment for urothelial carcinoma

p.13

Casirivimab + imdevimab (Ronapreve°) in early covid-19 with no signs of severity: possibly useful in patients at high risk of developing severe covid-19

p.14-15

Adverse Effects


Clopidogrel + a proton pump in­hibitor: increased mortality

p.16-18

Medically assisted reproduction in France: a review of adverse effects and failures

p.18-19

Vitamin D in dropper bottles for infants and children: accidental overdoses and eye exposure

p.20

Free  Lamotrigine: cardiac arrhythmias

p.21

Free  Biotin: interference with laboratory tests

p.21

Potassium salts + anti­cholinergic drugs: gastro­intestinal bleeding

p.22

Erenumab and other CGRP inhibitors: Raynaud's phenomenon

p.22

INN Common stem: -cain-, -caine

p.23

Tofacitinib: myo­cardial infarction and malignant tumours

p.23

Outlook


DNDi: a collaborative research and development model focused on patients' needs

p.24-26

Free  Alzheimer's: yet another unwelcome drug

p.26

Worth a read. Investigating Health and Medicine

p.27

Masthead


Free  Masthead

p.2

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe